Back to search results

Aspirin Dosing After Joint Replacement Surgery

This study is looking at whether taking 81 mg aspirin once a day is as good as taking it twice a day to prevent blood clots (venous thromboembolism or VTE) after total hip or knee replacement surgery. We want to see if one dose schedule is better at preventing these clots over 90 days. You might be able to join if you are 19 or older and planning to have a primary total hip or knee replacement. You cannot join if you have a history of blood clots, cancer, a known blood clotting disorder, a BMI over 40, need other blood thinners, or cannot take aspirin. The current status of this study is unclear.

Study design
This interventional study plans to include 5478 participants. It compares two different dosing schedules of 81 mg aspirin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 90 days to check for blood clots.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04295486

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Recruiting
PHASE2Ages 19+InterventionalPrevention
University of Miami
~5,478 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:Aspirin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of symptomatic thromboembolic events
Measured over 90 days

Conditions

Venous Thromboembolism

Explore related trials

Repair of hipTotal Knee Replacement

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Victor Hernandez, MD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Ramakanth Yakkanti, MD
[email protected]
502-689-3127
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\> 18 years of age
Planning to undergo a primary total hip or knee arthroplasty

Exclusion

High risk patients for VTE as defined by:
History of venous thromboembolism
Active malignancy
Known pro thrombotic condition
BMI \> 40
Patients requiring anticoagulation for pre-existing conditions
Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
Patients not fluent in the language of the informed consent form
Prisoners
Pregnancy
Reported to have mental illness or belonging to a vulnerable population

What this trial measures

  • Incidence of symptomatic thromboembolic events90 days

    Efficacy of prophylaxis will be reported as the number of reported incidence of symptomatic Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT).